Xiao C, Zhang X, Hou B, Wan P, Cao Z, Rao X
Discov Oncol. 2024; 15(1):847.
PMID: 39739214
PMC: 11685368.
DOI: 10.1007/s12672-024-01650-5.
Omole A, Zhao Z, Chang-Liao S, de Oliveira J, Boone C, Sutorus L
Nat Rev Bioeng. 2024; 2(11):916-929.
PMID: 39698315
PMC: 11655125.
DOI: 10.1038/s44222-024-00231-z.
Chen Y, Shi L, Yin W, Xia H, Lin C
Oncol Lett. 2024; 29(1):57.
PMID: 39606565
PMC: 11600704.
DOI: 10.3892/ol.2024.14803.
Jiacheng D, Jiayue C, Ying G, Shaohua W, Wenhui L, Xinyu H
Cell Biosci. 2024; 14(1):123.
PMID: 39334448
PMC: 11437992.
DOI: 10.1186/s13578-024-01305-6.
Luo Y, Lu J, Lei Z, Zhu H, Rao D, Wang T
Biomark Res. 2024; 12(1):74.
PMID: 39080807
PMC: 11289998.
DOI: 10.1186/s40364-024-00621-w.
Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors.
Darwish I, Alahmad W, Vinoth R
Heliyon. 2024; 10(10):e31317.
PMID: 38803937
PMC: 11129001.
DOI: 10.1016/j.heliyon.2024.e31317.
Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
Wang Y, Wang Z, Guo X, Cao Y, Xing H, Wang Y
Cancer Med. 2024; 13(9):e7218.
PMID: 38733169
PMC: 11087814.
DOI: 10.1002/cam4.7218.
Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy.
Kellermann G, Leulliot N, Cherfils-Vicini J, Blaud M, Brest P
Front Immunol. 2024; 15:1382236.
PMID: 38571942
PMC: 10989059.
DOI: 10.3389/fimmu.2024.1382236.
Applications of Intravital Imaging in Cancer Immunotherapy.
Deng D, Hao T, Lu L, Yang M, Zeng Z, Lovell J
Bioengineering (Basel). 2024; 11(3).
PMID: 38534538
PMC: 10968666.
DOI: 10.3390/bioengineering11030264.
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.
Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos I, Tsekenis G
Basic Res Cardiol. 2024; 120(1):263-286.
PMID: 38520533
PMC: 11790778.
DOI: 10.1007/s00395-024-01046-0.
A novel ultrasensitive chemiluminescence enzyme immunoassay by employment of a signal enhancement of horseradish peroxidase-luminol-hydrogen peroxide reaction for the quantitation of atezolizumab, a monoclonal antibody used for cancer immunotherapy.
Darwish I, Ali M, Alsalhi M, Zhang D
RSC Adv. 2024; 14(12):8167-8177.
PMID: 38469186
PMC: 10925958.
DOI: 10.1039/d4ra00202d.
Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
Mizote Y, Inoue T, Akazawa T, Kunimasa K, Tamiya M, Kumamoto Y
Cancer Sci. 2024; 115(4):1114-1128.
PMID: 38332689
PMC: 11007000.
DOI: 10.1111/cas.16099.
Targeting T regulatory (T) cells in immunotherapy-resistant cancers.
Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M
Cancer Drug Resist. 2024; 7:2.
PMID: 38318526
PMC: 10838381.
DOI: 10.20517/cdr.2023.46.
Circadian lifestyle determinants of immune checkpoint inhibitor efficacy.
Hughes B, Shanaz S, Ismail-Sutton S, Wreglesworth N, Subbe C, Innominato P
Front Oncol. 2023; 13:1284089.
PMID: 38111535
PMC: 10727689.
DOI: 10.3389/fonc.2023.1284089.
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet J
JHEP Rep. 2023; 5(12):100880.
PMID: 38074948
PMC: 10701119.
DOI: 10.1016/j.jhepr.2023.100880.
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
Huang S, Zheng G, Yang K
World J Surg Oncol. 2023; 21(1):349.
PMID: 37926852
PMC: 10626778.
DOI: 10.1186/s12957-023-03212-5.
Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
Rahman A, Janic B, Rahman T, Singh H, Ali H, Rattan R
Cancers (Basel). 2023; 15(20).
PMID: 37894298
PMC: 10605606.
DOI: 10.3390/cancers15204931.
Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood A, Batool S, Bhatti S, Ali A, Valko M, Jomova K
Front Immunol. 2023; 14:1202098.
PMID: 37529045
PMC: 10387524.
DOI: 10.3389/fimmu.2023.1202098.
Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI.
Liu C, Zhang Y, Gao X, Wang G
BMC Biol. 2023; 21(1):159.
PMID: 37468850
PMC: 10354926.
DOI: 10.1186/s12915-023-01658-3.
Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial.
Bujak J, Klek S, Balawejder M, Kociniak A, Wilkus K, Szatanek R
JMIR Res Protoc. 2023; 12:e45872.
PMID: 37440307
PMC: 10375398.
DOI: 10.2196/45872.
